Clinical Trial Update: Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures [Phase 3]

View source ↗

Summary

A Phase 3 study of adjunctive cannabidiol oral solution GWP42003-P in children with tuberous sclerosis complex, Dravet syndrome, or Lennox-Gastaut syndrome was …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dravet Syndrome
• Lennox-gastaut Syndrome
• Tuberous Sclerosis Complex

Drugs mentioned

• GWP42003-P (cannabidiol oral solution) (cannabidiol)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome | Phase 3 | Status: TERMINATED | Results posted: 2025-10-31